Cargando…

Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin

Binding of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol (C1), a biologically active substance, to bovine blood plasma albumin (BSA) at 293, 298, and 303 K was studied using fluorescence (steady state, synchronous, excitation/emission matrix) and FT-IR spectroscopy methods. The experimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoryan, Karine R., Shilajyan, Hasmik A., Zatikyan, Ashkhen, Aleksanyan, Iskuhi, Hambardzumyan, Lilit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084270/
https://www.ncbi.nlm.nih.gov/pubmed/35573272
http://dx.doi.org/10.1007/s00706-022-02919-7
_version_ 1784703575917592576
author Grigoryan, Karine R.
Shilajyan, Hasmik A.
Zatikyan, Ashkhen
Aleksanyan, Iskuhi
Hambardzumyan, Lilit
author_facet Grigoryan, Karine R.
Shilajyan, Hasmik A.
Zatikyan, Ashkhen
Aleksanyan, Iskuhi
Hambardzumyan, Lilit
author_sort Grigoryan, Karine R.
collection PubMed
description Binding of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol (C1), a biologically active substance, to bovine blood plasma albumin (BSA) at 293, 298, and 303 K was studied using fluorescence (steady state, synchronous, excitation/emission matrix) and FT-IR spectroscopy methods. The experimental results showed that C1 causes fluorescence quenching of BSA through both static and dynamic quenching mechanisms. The thermodynamic parameters, enthalpy and entropy change, for the static quenching were calculated to be − 35.73 kJ mol(−1) and − 35.34 J mol(−1) K(−1), which indicated that hydrogen bonding and van der Waals interactions were the predominant intermolecular forces regulating C1–BSA interactions. Distance between donor and acceptor (2.14, 2.26, and 2.30 nm) depending on the temperature, obtained from intrinsic Förster resonance energy transfer calculations, revealed the static quenching mechanism of BSA fluorescence in 0–3.0 × 10(−5) mol/dm(3) concentration range of C1. The micro-environmental and conformational changes in BSA structure, established by synchronous, excitation/emission matrices and FT-IR spectra showed the changes in the BSA secondary structure. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9084270
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-90842702022-05-10 Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin Grigoryan, Karine R. Shilajyan, Hasmik A. Zatikyan, Ashkhen Aleksanyan, Iskuhi Hambardzumyan, Lilit Monatsh Chem Original Paper Binding of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol (C1), a biologically active substance, to bovine blood plasma albumin (BSA) at 293, 298, and 303 K was studied using fluorescence (steady state, synchronous, excitation/emission matrix) and FT-IR spectroscopy methods. The experimental results showed that C1 causes fluorescence quenching of BSA through both static and dynamic quenching mechanisms. The thermodynamic parameters, enthalpy and entropy change, for the static quenching were calculated to be − 35.73 kJ mol(−1) and − 35.34 J mol(−1) K(−1), which indicated that hydrogen bonding and van der Waals interactions were the predominant intermolecular forces regulating C1–BSA interactions. Distance between donor and acceptor (2.14, 2.26, and 2.30 nm) depending on the temperature, obtained from intrinsic Förster resonance energy transfer calculations, revealed the static quenching mechanism of BSA fluorescence in 0–3.0 × 10(−5) mol/dm(3) concentration range of C1. The micro-environmental and conformational changes in BSA structure, established by synchronous, excitation/emission matrices and FT-IR spectra showed the changes in the BSA secondary structure. GRAPHICAL ABSTRACT: [Image: see text] Springer Vienna 2022-05-09 2022 /pmc/articles/PMC9084270/ /pubmed/35573272 http://dx.doi.org/10.1007/s00706-022-02919-7 Text en © Springer-Verlag GmbH Austria, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Grigoryan, Karine R.
Shilajyan, Hasmik A.
Zatikyan, Ashkhen
Aleksanyan, Iskuhi
Hambardzumyan, Lilit
Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title_full Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title_fullStr Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title_full_unstemmed Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title_short Spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
title_sort spectroscopic analysis of 2-(5-mercapto-1,3,4-oxadiazol-2-yl)-6-methylquinolin-4-ol binding to blood plasma albumin
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084270/
https://www.ncbi.nlm.nih.gov/pubmed/35573272
http://dx.doi.org/10.1007/s00706-022-02919-7
work_keys_str_mv AT grigoryankariner spectroscopicanalysisof25mercapto134oxadiazol2yl6methylquinolin4olbindingtobloodplasmaalbumin
AT shilajyanhasmika spectroscopicanalysisof25mercapto134oxadiazol2yl6methylquinolin4olbindingtobloodplasmaalbumin
AT zatikyanashkhen spectroscopicanalysisof25mercapto134oxadiazol2yl6methylquinolin4olbindingtobloodplasmaalbumin
AT aleksanyaniskuhi spectroscopicanalysisof25mercapto134oxadiazol2yl6methylquinolin4olbindingtobloodplasmaalbumin
AT hambardzumyanlilit spectroscopicanalysisof25mercapto134oxadiazol2yl6methylquinolin4olbindingtobloodplasmaalbumin